Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib combined with SHR-A1811 in HER2-expressing advanced solid tumors
CTR20220953Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, trastuzumab rezetecan in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2022; status: active.
02
Drugs
fluzoparibtrastuzumab rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220953.